An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia

Roche

Status: Completed

Conditions: Lymphocytic Leukemia, Chronic

Study type: Observational

Funder types: Industry

Identifiers

NCT01488162

ML25664

Details and patient eligibility

About

This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.

Enrollment: 327 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/=18 years of age
• Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) with first or second relapse
• Previous treatment with MabThera/Rituxan
• MabThera/Rituxan treatment planned for current relapse

Exclusion criteria

• Richter syndrome
• Life expectancy <6 months

Trial design

327 participants in 1 patient group

Cohort